Attack the cancer, not the patient


Our innovative technology provides a step-change in the selectivity and potency of targeted cancer drugs 

As novel biotherapeutics progress through the clinic and on to the market, toxicities generated due to the expression of the targeted antigens on healthy tissues represent a key concern linked with significant long-term morbidities and mortality.

Through direct experience in the NHS and with a leading Antibody Drug Conjugate ("ADC") sector specialist, the BiVictriX team has developed the Bi-Cygni    technology. Bi-Cygni    therapeutics target a novel cancer-restricted cell-surface fingerprint, which is absent from healthy cells. Enabling the development of anti-cancer drugs with a marked increase in tumour selectivity, together with improved potency.



Problem: Lack of truly tumour-specific antigens available


Improves therapeutic index through targeting a unique cancer-specific cell surface antigen fingerprint, absent from healthy cells


Key Personnel

Norman Molyneux 


Tiffany Thorn

Founder & CEO

For any partnership or investment enquiries

BiVictriX Therapeutics Ltd.


Bio Hub   |   Alderley Park  |   Alderley Edge   |    Cheshire    |    SK10 4TG   |    UK


The OpTIC Centre  |  St Asaph Business Park  |  St Asaph  |   Wales  |   LL17 0JD  |   UK